EA018608B1 - Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола и ингибитор dpp iv - Google Patents

Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола и ингибитор dpp iv Download PDF

Info

Publication number: EA018608B1
Authority: EA; Eurasian Patent Office
Prior art keywords: inhibitor; pharmaceutical composition; glucose; substituted benzene; benzene derivative
Prior art date: 2007-08-16

Application number

EA201000321A

Other languages

English (en)

Russian (ru)

Other versions

EA201000321A1 (ru

Inventor

Клаус Дуги

Михаэль Марк

Лео Томас

Франк Химмельсбах

Original Assignee

Бёрингер Ингельхайм Интернациональ Гмбх

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-16

Filing date

2008-08-15

Publication date

2013-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39870130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA018608(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-08-15 Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх

2010-08-30 Publication of EA201000321A1 publication Critical patent/EA201000321A1/ru

2013-09-30 Publication of EA018608B1 publication Critical patent/EA018608B1/ru

Links

239000003112 inhibitor Substances 0.000 title claims abstract description 100
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 92
125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
150000001555 benzenes Chemical class 0.000 claims abstract description 91
208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 62
150000003839 salts Chemical class 0.000 claims abstract description 37
230000001575 pathological effect Effects 0.000 claims abstract description 26
201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 25
208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 17
201000001421 hyperglycemia Diseases 0.000 claims abstract description 12
208000030159 metabolic disease Diseases 0.000 claims abstract description 9
239000008103 glucose Substances 0.000 claims description 126
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 125
125000005640 glucopyranosyl group Chemical group 0.000 claims description 93
210000004369 blood Anatomy 0.000 claims description 56
239000008280 blood Substances 0.000 claims description 56
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 51
-1 4-methylquinazolin-2-yl Chemical group 0.000 claims description 48
239000000203 mixture Substances 0.000 claims description 47
206010022489 Insulin Resistance Diseases 0.000 claims description 43
230000002641 glycemic effect Effects 0.000 claims description 34
239000002552 dosage form Substances 0.000 claims description 25
238000009097 single-agent therapy Methods 0.000 claims description 24
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 23
206010012601 diabetes mellitus Diseases 0.000 claims description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
210000004153 islets of langerhan Anatomy 0.000 claims description 21
208000008589 Obesity Diseases 0.000 claims description 20
235000020824 obesity Nutrition 0.000 claims description 20
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 18
201000010099 disease Diseases 0.000 claims description 16
208000001145 Metabolic Syndrome Diseases 0.000 claims description 15
208000004611 Abdominal Obesity Diseases 0.000 claims description 14
206010060378 Hyperinsulinaemia Diseases 0.000 claims description 14
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 14
201000008980 hyperinsulinism Diseases 0.000 claims description 14
230000001771 impaired effect Effects 0.000 claims description 14
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
230000003451 hyperinsulinaemic effect Effects 0.000 claims description 13
206010033307 Overweight Diseases 0.000 claims description 11
230000037396 body weight Effects 0.000 claims description 11
210000002966 serum Anatomy 0.000 claims description 10
239000007787 solid Substances 0.000 claims description 10
230000037406 food intake Effects 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
229940075420 xanthine Drugs 0.000 claims description 9
206010065941 Central obesity Diseases 0.000 claims description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
230000002159 abnormal effect Effects 0.000 claims description 7
230000001419 dependent effect Effects 0.000 claims description 7
210000004185 liver Anatomy 0.000 claims description 7
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 7
229960003105 metformin Drugs 0.000 claims description 7
210000002784 stomach Anatomy 0.000 claims description 7
208000002249 Diabetes Complications Diseases 0.000 claims description 6
238000009825 accumulation Methods 0.000 claims description 6
230000035487 diastolic blood pressure Effects 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 6
150000003626 triacylglycerols Chemical class 0.000 claims description 6
230000004584 weight gain Effects 0.000 claims description 6
235000019786 weight gain Nutrition 0.000 claims description 6
230000007850 degeneration Effects 0.000 claims description 5
208000017169 kidney disease Diseases 0.000 claims description 5
230000035488 systolic blood pressure Effects 0.000 claims description 5
230000004580 weight loss Effects 0.000 claims description 5
108010054147 Hemoglobins Proteins 0.000 claims description 4
102000001554 Hemoglobins Human genes 0.000 claims description 4
208000031773 Insulin resistance syndrome Diseases 0.000 claims description 4
235000012000 cholesterol Nutrition 0.000 claims description 4
230000006872 improvement Effects 0.000 claims description 4
230000003914 insulin secretion Effects 0.000 claims description 4
208000028867 ischemia Diseases 0.000 claims description 4
201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 claims description 4
208000010125 myocardial infarction Diseases 0.000 claims description 4
230000002093 peripheral effect Effects 0.000 claims description 4
206010003210 Arteriosclerosis Diseases 0.000 claims description 3
208000002177 Cataract Diseases 0.000 claims description 3
208000017442 Retinal disease Diseases 0.000 claims description 3
206010038923 Retinopathy Diseases 0.000 claims description 3
208000006011 Stroke Diseases 0.000 claims description 3
208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
210000001367 artery Anatomy 0.000 claims description 3
230000003902 lesion Effects 0.000 claims description 3
201000001119 neuropathy Diseases 0.000 claims description 3
230000007823 neuropathy Effects 0.000 claims description 3
208000033808 peripheral neuropathy Diseases 0.000 claims description 3
210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 2
206010056997 Impaired fasting glucose Diseases 0.000 claims description 2
238000011287 therapeutic dose Methods 0.000 claims description 2
241001274613 Corvus frugilegus Species 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 39
230000002265 prevention Effects 0.000 abstract description 8
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 5
YZGOOQZXQOPQNT-DNNBANOASA-N (2r,3r,4s,5s,6r)-2-[4-chloro-3-[[4-[(3s)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@]1(O)C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 YZGOOQZXQOPQNT-DNNBANOASA-N 0.000 abstract 1
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 69
239000000243 solution Substances 0.000 description 63
150000001875 compounds Chemical class 0.000 description 60
238000000034 method Methods 0.000 description 56
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
102000004877 Insulin Human genes 0.000 description 34
108090001061 Insulin Proteins 0.000 description 34
229940125396 insulin Drugs 0.000 description 34
238000002360 preparation method Methods 0.000 description 34
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
238000001819 mass spectrum Methods 0.000 description 26
239000002904 solvent Substances 0.000 description 25
239000003814 drug Substances 0.000 description 22
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
239000004480 active ingredient Substances 0.000 description 19
229910052938 sodium sulfate Inorganic materials 0.000 description 19
235000011152 sodium sulphate Nutrition 0.000 description 19
230000007423 decrease Effects 0.000 description 18
239000003826 tablet Substances 0.000 description 18
229940079593 drug Drugs 0.000 description 17
241001465754 Metazoa Species 0.000 description 15
239000000047 product Substances 0.000 description 15
230000002829 reductive effect Effects 0.000 description 15
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 14
239000000284 extract Substances 0.000 description 14
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
230000000694 effects Effects 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
239000002775 capsule Substances 0.000 description 11
MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 11
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
239000007864 aqueous solution Substances 0.000 description 10
201000003077 normal pressure hydrocephalus Diseases 0.000 description 10
QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 10
229960004937 saxagliptin Drugs 0.000 description 10
108010033693 saxagliptin Proteins 0.000 description 10
229960004034 sitagliptin Drugs 0.000 description 10
206010018429 Glucose tolerance impaired Diseases 0.000 description 9
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
238000011321 prophylaxis Methods 0.000 description 9
238000006722 reduction reaction Methods 0.000 description 9
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 9
229960001254 vildagliptin Drugs 0.000 description 9
208000001280 Prediabetic State Diseases 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
239000012267 brine Substances 0.000 description 8
239000003085 diluting agent Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000012074 organic phase Substances 0.000 description 8
230000009467 reduction Effects 0.000 description 8
238000010898 silica gel chromatography Methods 0.000 description 8
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
239000000126 substance Substances 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
238000010171 animal model Methods 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000010411 cooking Methods 0.000 description 6
238000001816 cooling Methods 0.000 description 6
235000019197 fats Nutrition 0.000 description 6
230000006870 function Effects 0.000 description 6
238000003756 stirring Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
208000024172 Cardiovascular disease Diseases 0.000 description 5
108010010234 HDL Lipoproteins Proteins 0.000 description 5
102000015779 HDL Lipoproteins Human genes 0.000 description 5
241000700159 Rattus Species 0.000 description 5
229960001667 alogliptin Drugs 0.000 description 5
ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 5
229910052786 argon Inorganic materials 0.000 description 5
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000002349 favourable effect Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000003960 organic solvent Substances 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
229920002261 Corn starch Polymers 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
206010019708 Hepatic steatosis Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
235000011054 acetic acid Nutrition 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000008859 change Effects 0.000 description 4
229940125904 compound 1 Drugs 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
235000003642 hunger Nutrition 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
231100000682 maximum tolerated dose Toxicity 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 3
229940126062 Compound A Drugs 0.000 description 3
URRAHSMDPCMOTH-LNLFQRSKSA-N Denagliptin Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
102000051325 Glucagon Human genes 0.000 description 3
108060003199 Glucagon Proteins 0.000 description 3
102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
208000013016 Hypoglycemia Diseases 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical class OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
229950010300 denagliptin Drugs 0.000 description 3
235000005686 eating Nutrition 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
229960004666 glucagon Drugs 0.000 description 3
239000008187 granular material Substances 0.000 description 3
150000004677 hydrates Chemical class 0.000 description 3
230000002218 hypoglycaemic effect Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
230000007774 longterm Effects 0.000 description 3
229940098779 methanesulfonic acid Drugs 0.000 description 3
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000012453 solvate Substances 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
PQRRCNXYHIDDER-UHFFFAOYSA-N (2-bromo-4-fluorophenyl)-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)C1=CC=C(F)C=C1Br PQRRCNXYHIDDER-UHFFFAOYSA-N 0.000 description 2
VPKRZSLXEQBLHP-UHFFFAOYSA-N (2-bromo-4-methoxyphenyl)-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)C1=CC=C(OC)C=C1Br VPKRZSLXEQBLHP-UHFFFAOYSA-N 0.000 description 2
DNKSRIHGWPCDPM-UHFFFAOYSA-N (2-bromo-5-iodophenyl)-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)C1=CC(I)=CC=C1Br DNKSRIHGWPCDPM-UHFFFAOYSA-N 0.000 description 2
MSCWUTTUQLYJFT-QMBKNIKNSA-N (2s,4s)-1-[(2s)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 MSCWUTTUQLYJFT-QMBKNIKNSA-N 0.000 description 2
YNLGFXOBRXSMJZ-UHFFFAOYSA-N (4-cyclopropylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1CC1 YNLGFXOBRXSMJZ-UHFFFAOYSA-N 0.000 description 2
IPTYFZLHONGTGW-UHFFFAOYSA-N 1-bromo-2-(chloromethyl)-4-iodobenzene Chemical compound ClCC1=CC(I)=CC=C1Br IPTYFZLHONGTGW-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
PZNOBCFGAOXZOL-UHFFFAOYSA-N 4-bromo-2-[(4-ethylphenyl)methyl]-6-methoxybenzonitrile Chemical compound C1=CC(CC)=CC=C1CC1=CC(Br)=CC(OC)=C1C#N PZNOBCFGAOXZOL-UHFFFAOYSA-N 0.000 description 2
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
206010054044 Diabetic microangiopathy Diseases 0.000 description 2
YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
208000004930 Fatty Liver Diseases 0.000 description 2
239000001828 Gelatine Substances 0.000 description 2
206010018473 Glycosuria Diseases 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108010076181 Proinsulin Proteins 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
KEJICOXJTRHYAK-XFULWGLBSA-N alogliptin benzoate Chemical compound OC(=O)C1=CC=CC=C1.C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 KEJICOXJTRHYAK-XFULWGLBSA-N 0.000 description 2
229960000447 alogliptin benzoate Drugs 0.000 description 2
239000003708 ampul Substances 0.000 description 2
229940127003 anti-diabetic drug Drugs 0.000 description 2
239000003472 antidiabetic agent Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000012043 crude product Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
201000009101 diabetic angiopathy Diseases 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
208000010706 fatty liver disease Diseases 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
230000035780 glucosuria Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000003284 homeostatic effect Effects 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
238000000465 moulding Methods 0.000 description 2
230000009707 neogenesis Effects 0.000 description 2
206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000009103 reabsorption Effects 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
235000002020 sage Nutrition 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
229960004115 sitagliptin phosphate Drugs 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
231100000240 steatosis hepatitis Toxicity 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
RTZRUVMEWWPNRR-UHFFFAOYSA-N tert-butyl n-(3-iodo-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C2NC=C(I)C2=C1 RTZRUVMEWWPNRR-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
WWSQWMGRBDEATJ-UHFFFAOYSA-N (2-bromo-5-iodo-4-methoxyphenyl)-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)C1=CC(I)=C(OC)C=C1Br WWSQWMGRBDEATJ-UHFFFAOYSA-N 0.000 description 1
HNXIATMNXSMCNU-UHFFFAOYSA-N (2-bromo-5-iodo-4-methylphenyl)-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)C1=CC(I)=C(C)C=C1Br HNXIATMNXSMCNU-UHFFFAOYSA-N 0.000 description 1
WDXHGFYJUQMFDV-UHFFFAOYSA-N (2-bromo-5-iodophenyl)methanol Chemical compound OCC1=CC(I)=CC=C1Br WDXHGFYJUQMFDV-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
HMARMCWDGBFBLF-UHFFFAOYSA-N 1-bromo-2-[(4-ethylphenyl)methyl]-4-iodobenzene Chemical compound C1=CC(CC)=CC=C1CC1=CC(I)=CC=C1Br HMARMCWDGBFBLF-UHFFFAOYSA-N 0.000 description 1
JRDNBWVMEFUNCQ-UHFFFAOYSA-N 1-bromo-4-cyclopropylbenzene Chemical compound C1=CC(Br)=CC=C1C1CC1 JRDNBWVMEFUNCQ-UHFFFAOYSA-N 0.000 description 1
GCQNURAETVDXDM-UHFFFAOYSA-N 1-bromo-4-iodo-2-(phenoxymethyl)benzene Chemical compound BrC1=CC=C(I)C=C1COC1=CC=CC=C1 GCQNURAETVDXDM-UHFFFAOYSA-N 0.000 description 1
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
BLSDRZYRALDRRF-UHFFFAOYSA-N 2-bromo-5-iodo-4-methylbenzoic acid Chemical compound CC1=CC(Br)=C(C(O)=O)C=C1I BLSDRZYRALDRRF-UHFFFAOYSA-N 0.000 description 1
QPKKBDSNZFSSOD-UHFFFAOYSA-N 2-bromo-5-iodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC=C1Br QPKKBDSNZFSSOD-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
UMKCLSAMAGFYDD-UHFFFAOYSA-N 4-(2,4,5-trifluorophenyl)butanal Chemical compound FC1=CC(F)=C(CCCC=O)C=C1F UMKCLSAMAGFYDD-UHFFFAOYSA-N 0.000 description 1
TZHQWUAOIWRFSW-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzonitrile Chemical compound FC1=CC(Br)=CC(F)=C1C#N TZHQWUAOIWRFSW-UHFFFAOYSA-N 0.000 description 1
YPMOAQISONSSNL-UHFFFAOYSA-N 8-hydroxyoctyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCO YPMOAQISONSSNL-UHFFFAOYSA-N 0.000 description 1
102000011690 Adiponectin Human genes 0.000 description 1
108010076365 Adiponectin Proteins 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
101100324465 Caenorhabditis elegans arr-1 gene Proteins 0.000 description 1
101710152019 Centromere-binding protein 1 Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
206010063547 Diabetic macroangiopathy Diseases 0.000 description 1
206010056340 Diabetic ulcer Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
206010016262 Fatty liver alcoholic Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229910017976 MgO 4 Inorganic materials 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
102000005445 Neuronal Apoptosis-Inhibitory Protein Human genes 0.000 description 1
108010006696 Neuronal Apoptosis-Inhibitory Protein Proteins 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
206010042135 Stomatitis necrotising Diseases 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
206010047571 Visual impairment Diseases 0.000 description 1
230000009102 absorption Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
238000002266 amputation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000007919 dispersible tablet Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
238000000132 electrospray ionisation Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
WKGJQUDONDDASX-UHFFFAOYSA-N ethyl 2-(4-ethylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(CC)C=C1 WKGJQUDONDDASX-UHFFFAOYSA-N 0.000 description 1
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
230000001610 euglycemic effect Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
229930182478 glucoside Natural products 0.000 description 1
150000008131 glucosides Chemical class 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
231100000206 health hazard Toxicity 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
108010049074 hemoglobin B Proteins 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000004026 insulin derivative Substances 0.000 description 1
210000002570 interstitial cell Anatomy 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229940090473 januvia Drugs 0.000 description 1
210000001985 kidney epithelial cell Anatomy 0.000 description 1
208000006443 lactic acidosis Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002032 methanolic fraction Substances 0.000 description 1
WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
210000000110 microvilli Anatomy 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
238000007491 morphometric analysis Methods 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
201000008585 noma Diseases 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000006308 propyl amino group Chemical group 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
210000000512 proximal kidney tubule Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008060 renal absorption Effects 0.000 description 1
230000013878 renal filtration Effects 0.000 description 1
230000030558 renal glucose absorption Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
102200141019 rs11545137 Human genes 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
208000029257 vision disease Diseases 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Biophysics (AREA)
Hematology (AREA)
Obesity (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

EA201000321A 2007-08-16 2008-08-15 Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола и ингибитор dpp iv EA018608B1 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07114459		2007-08-16
PCT/EP2008/060736 WO2009022007A1 (en)	2007-08-16	2008-08-15	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative

Publications (2)

Publication Number	Publication Date
EA201000321A1 EA201000321A1 (ru)	2010-08-30
EA018608B1 true EA018608B1 (ru)	2013-09-30

Family

ID=39870130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EA201000321A EA018608B1 (ru)	2007-08-16	2008-08-15	Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола и ингибитор dpp iv

Country Status (39)

Country	Link
US (1)	US8551957B2 (pt)
EP (4)	EP2187879B1 (pt)
JP (1)	JP5595914B2 (pt)
KR (1)	KR101491554B1 (pt)
CN (3)	CN104288166A (pt)
AR (2)	AR067970A1 (pt)
AU (1)	AU2008288407B2 (pt)
BR (1)	BRPI0815331B8 (pt)
CA (1)	CA2696558C (pt)
CL (1)	CL2008002427A1 (pt)
CO (1)	CO6251239A2 (pt)
CY (2)	CY1118308T1 (pt)
DK (1)	DK2187879T3 (pt)
EA (1)	EA018608B1 (pt)
EC (1)	ECSP109977A (pt)
ES (1)	ES2602748T3 (pt)
HK (2)	HK1201721A1 (pt)
HR (1)	HRP20170022T1 (pt)
HU (2)	HUE030158T2 (pt)
IL (1)	IL202886A (pt)
LT (2)	LT2187879T (pt)
MA (1)	MA31612B1 (pt)
ME (1)	ME02573B (pt)
MX (1)	MX2010001696A (pt)
MY (1)	MY152037A (pt)
NL (1)	NL300872I2 (pt)
NO (1)	NO2017020I2 (pt)
NZ (1)	NZ583242A (pt)
PE (1)	PE20090938A1 (pt)
PL (1)	PL2187879T3 (pt)
PT (1)	PT2187879T (pt)
RS (1)	RS55205B1 (pt)
SI (1)	SI2187879T1 (pt)
TN (1)	TN2010000073A1 (pt)
TW (2)	TW201436798A (pt)
UA (1)	UA100384C2 (pt)
UY (1)	UY31296A1 (pt)
WO (1)	WO2009022007A1 (pt)
ZA (1)	ZA200909105B (pt)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN103030617A (zh) *	2004-03-16	2013-04-10	贝林格尔.英格海姆国际有限公司	吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AU2006289093A1 (en) *	2005-09-08	2007-03-15	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PE20080697A1 (es)	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP2540725A1 (de)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
KR20090042227A (ko)	2006-06-06	2009-04-29	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
WO2008049923A1 (en) *	2006-10-27	2008-05-02	Boehringer Ingelheim International Gmbh	CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CL2008002425A1 (es) *	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
JP2011504505A (ja) *	2007-11-21	2011-02-10	デコードジェネティクスイーエイチエフ	肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
EP2240028B1 (en)	2007-12-06	2016-07-20	Intra-Cellular Therapies, Inc.	Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
AU2009270936B2 (en)	2008-07-15	2014-12-18	Theracos, Inc.	Deuterated benzylbenzene derivatives and methods of use
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
US20240148737A1 (en) *	2008-10-16	2024-05-09	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
UY32177A (es) *	2008-10-16	2010-05-31	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
EP2367431B1 (en)	2008-12-06	2015-08-05	Intra-Cellular Therapies, Inc.	Organic compounds
BRPI0922809A2 (pt)	2008-12-06	2018-05-29	Intracellular Therapies Inc	compostos orgânicos
EP2367430B1 (en)	2008-12-06	2014-08-13	Intra-Cellular Therapies, Inc.	Organic compounds
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) *	2009-01-29	2011-03-16	Boehringer Ingelheim Int	Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
DK2396005T3 (da) *	2009-02-13	2026-02-09	Boehringer Ingelheim Int	Sglt2 hæmmer til at forbedre glykæmisk kontrol
UY32427A (es) *	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
AU2016213789B2 (en) *	2009-02-13	2018-01-18	Boehringer Ingelheim International Gmbh	SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
JP5685550B2 (ja) *	2009-02-13	2015-03-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
US20110014284A1 (en) *	2009-02-13	2011-01-20	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
SG2014012553A (en)	2009-04-16	2014-05-29	Taisho Pharmaceutical Co Ltd	Pharmaceutical compositions
EA020798B1 (ru) *	2009-09-30	2015-01-30	Бёрингер Ингельхайм Интернациональ Гмбх	СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
PT2486029E (pt)	2009-09-30	2015-10-14	Boehringer Ingelheim Int	Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
UY32919A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2368552A1 (en)	2010-03-25	2011-09-28	Boehringer Ingelheim Vetmedica GmbH	1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
WO2011153136A1 (en)	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
WO2011153135A1 (en)	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
WO2011161161A1 (en)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Diabetes therapy
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CA2835332C (en) *	2011-05-10	2019-03-26	Sandoz Ag	Polymorph of linagliptin benzoate
US20130035298A1 (en)	2011-07-08	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US8883800B2 (en)	2011-07-15	2014-11-11	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013098775A1 (en) *	2011-12-28	2013-07-04	Dr. Reddy's Laboratories Limited	Improved process for preparation of pure linagliptin
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6374862B2 (ja) *	2012-05-24	2018-08-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
PT2981269T (pt)	2013-04-04	2023-10-10	Boehringer Ingelheim Vetmedica Gmbh	Tratamento de distúrbios metabólicos em animais equinos
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) *	2013-04-05	2019-02-21	Boehringer Ingelheim Int	Empagliflozinin terapötik kullanımları.
US20160000816A1 (en) *	2013-04-05	2016-01-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en) *	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh)	2013-04-05	2016-07-15	勃林格殷格翰国际有限公司	依帕列净的治疗用途
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
EP4678242A3 (en) *	2013-04-18	2026-03-18	Boehringer Ingelheim International GmbH	Pharmaceutical composition, methods for treating and uses thereof
ES2969764T3 (es)	2013-12-17	2024-05-22	Boehringer Ingelheim Vetmedica Gmbh	Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
US9902751B2 (en)	2013-12-30	2018-02-27	Mylan Laboratories Limited	Process for the preparation of empagliflozin
CN115671290A (zh) *	2014-01-23	2023-02-03	勃林格殷格翰动物保健有限公司	犬科动物中代谢紊乱的治疗
EP3110449B1 (en)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medical use of a dpp-4 inhibitor
WO2015150299A2 (en)	2014-04-01	2015-10-08	Boehringer Ingelheim Vetmedica Gmbh	Treatment of metabolic disorders in equine animals
CN103965020B (zh) *	2014-05-06	2015-09-09	启东东岳药业有限公司	制备5-碘-2-溴苄醇的方法
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
WO2016046150A1 (en)	2014-09-25	2016-03-31	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
KR102659761B1 (ko)	2015-08-27	2024-04-24	베링거잉겔하임베트메디카게엠베하	Sglt-2 억제제를 포함하는 액상 약제학적 조성물
BR112018016001A2 (pt) *	2016-03-16	2018-12-18	Boehringer Ingelheim International Gmbh	composição farmacêutica, métodos de tratamento e usos da mesma
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
KR20190084096A (ko)	2016-11-10	2019-07-15	베링거 인겔하임 인터내셔날 게엠베하	약제학적 조성물, 치료 방법 및 이의 용도
EP3841127A2 (en)	2018-08-21	2021-06-30	Kaleido Biosciences, Inc.	Oligosaccharide compositions and methods of use thereof for reducing ammonia levels
WO2020058095A1 (en)	2018-09-19	2020-03-26	Galenicum Health S.L.U.	Pharmaceutical compositions of empagliflozin
CA3180674A1 (en)	2020-04-22	2021-10-28	Bayer Aktiengesellschaft	Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
CN121202677B (zh) *	2025-11-26	2026-03-06	泉州师范学院	一种通过硼碳氮-镍光催化芳基乙酸和芳基卤化物的方法

Citations (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020137903A1 (en) *	1999-10-12	2002-09-26	Bruce Ellsworth	C-aryl glucoside SGLT2 inhibitors and method
WO2003037327A1 (en) *	2001-10-26	2003-05-08	F. Hoffmann-La-Roche Ag	N-substituted pyrrolidin derivatives as dipeptidyl peptidase iv inhibitors
US20030114390A1 (en) *	2001-03-13	2003-06-19	Washburn William N.	C-aryl glucoside SGLT2 inhibitors and method
WO2004018468A2 (de) *	2002-08-21	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel
EP1406873A2 (en) *	2001-06-27	2004-04-14	Smithkline Beecham Corporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2004050658A1 (de) *	2002-12-03	2004-06-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel
WO2005000848A1 (en) *	2003-06-20	2005-01-06	F. Hoffmann-La Roche Ag	Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors
EP1500403A1 (en) *	2002-04-26	2005-01-26	Ajinomoto Co., Inc.	Preventive/remedy for diabetes
WO2005049022A2 (en) *	2003-11-17	2005-06-02	Novartis Ag	Use of dipeptidyl peptidase iv inhibitors
WO2005085246A1 (de) *	2004-02-18	2005-09-15	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
WO2005092877A1 (de) *	2004-03-16	2005-10-06	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1586571A1 (en) *	2004-03-15	2005-10-19	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2005116014A1 (en) *	2004-05-12	2005-12-08	Pfizer Products Inc.	Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
WO2006029769A1 (de) *	2004-09-14	2006-03-23	Boehringer Ingelheim International Gmbh	Neue 3-methyl-7-butinyl-xanthine, deren herstellung und deren verwendung als arzneimittel
WO2006040625A1 (en) *	2004-10-12	2006-04-20	Glenmark Pharmaceuticals S.A.	Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation
US20070060530A1 (en) *	2005-09-14	2007-03-15	Christopher Ronald J	Administration of dipeptidyl peptidase inhibitors
WO2007093610A1 (en) *	2006-02-15	2007-08-23	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
WO2007128761A2 (de) *	2006-05-04	2007-11-15	Boehringer Ingelheim International Gmbh	Verwendungen von dpp iv inhibitoren
US20070299076A1 (en) *	2006-06-21	2007-12-27	Pfizer Inc	Substituted 3-Amino-Pyrrolidino-4-Lactams
WO2008055870A1 (en) *	2006-11-06	2008-05-15	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008055940A2 (en) *	2006-11-09	2008-05-15	Boehringer Ingelheim International Gmbh	Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
NL167151C (nl) *	1971-04-09	1981-11-16	Acf Chemiefarma Nv	Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen.
DE2758025A1 (de)	1977-12-24	1979-07-12	Bayer Ag	Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
NO154918C (no) *	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2951135A1 (de) *	1979-12-19	1981-06-25	Hoechst Ag, 6230 Frankfurt	Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4602023A (en) *	1985-06-03	1986-07-22	Warner-Lambert Company	Diphenic acid monoamides
US4786755A (en) *	1985-06-03	1988-11-22	Warner-Lambert Company	Diphenic acid monoamides
US4786023A (en) *	1987-08-19	1988-11-22	Harris Leverett D	Drafting implement holder
DE122010000020I1 (de) *	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
AU6024998A (en)	1997-01-15	1998-08-07	Glycomed Incorporated	Aryl c-glycoside compounds and sulfated esters thereof
EP2583675A1 (en) *	1998-02-02	2013-04-24	Trustees Of Tufts College	Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6613806B1 (en) *	1999-01-29	2003-09-02	Basf Corporation	Enhancement of the efficacy of benzoylbenzenes
KR100591585B1 (ko)	1999-08-31	2006-06-20	깃세이 야쿠힌 고교 가부시키가이샤	글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
PH12000002657B1 (en) *	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
EP1743655B1 (en)	2000-01-21	2014-06-25	Novartis AG	Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
JP4456768B2 (ja)	2000-02-02	2010-04-28	壽製薬株式会社	Ｃ−配糖体を含有する薬剤
US6627611B2 (en) *	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
GB0014969D0 (en)	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
AU2001268958B2 (en)	2000-07-04	2006-03-09	Novo Nordisk A/S	Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
SK287811B6 (sk) *	2000-09-29	2011-10-04	Kissei Pharmaceutical Co., Ltd	Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu
EP1344780A4 (en)	2000-11-30	2004-01-28	Kissei Pharmaceutical	GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
CA2433090A1 (en) *	2000-12-27	2002-07-04	Kyowa Hakko Kogyo Co., Ltd.	Dipeptidyl peptidase iv inhibitor
ATE431830T1 (de)	2000-12-28	2009-06-15	Kissei Pharmaceutical	Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
TWI255817B (en) *	2001-02-14	2006-06-01	Kissei Pharmaceutical	Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
EP1368349B1 (de)	2001-02-24	2007-02-14	Boehringer Ingelheim Pharma GmbH & Co.KG	Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
JP3698067B2 (ja) *	2001-03-30	2005-09-21	Ｊｓｒ株式会社	電子吸引性基および電子供与性基を有するモノマー、それを用いた共重合体、ならびにプロトン伝導膜
AU2002338643A1 (en)	2001-04-10	2002-10-28	Millennium Pharmaceuticals, Inc.	68723, sodium/glucose cotransporter family members and uses therefor
AU2002254567B2 (en) *	2001-04-11	2007-10-11	Bristol-Myers Squibb Company	Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
US6869947B2 (en) *	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
DE60225556D1 (de)	2001-07-03	2008-04-24	Novo Nordisk As	Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003020737A1 (en)	2001-09-05	2003-03-13	Bristol-Myers Squibb Company	O-pyrazole glucoside sglt2 inhibitors and method of use
AU2002331311A1 (en)	2001-09-19	2003-04-01	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
WO2003031458A1 (en)	2001-10-12	2003-04-17	Dana-Farber Cancer Institute	Methods for synthesis of diarylmethanes
ATE407678T1 (de) *	2001-10-17	2008-09-15	Boehringer Ingelheim Pharma	Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
AU2003201274A1 (en)	2002-01-11	2003-07-24	Novo Nordisk A/S	Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
DE10231370B4 (de)	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en)	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
RU2356906C2 (ru) *	2002-08-08	2009-05-27	Киссеи Фармасьютикал Ко., Лтд.	Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения
US7407955B2 (en) *	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238477A1 (de)	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238470A1 (de)	2002-08-22	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10251927A1 (de)	2002-11-08	2004-05-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7482337B2 (en) *	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
JP3567162B1 (ja)	2002-11-20	2004-09-22	日本たばこ産業株式会社	４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
SK2662004A3 (sk)	2002-11-20	2005-06-02	Japan Tobacco, Inc.	Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
DE10254304A1 (de)	2002-11-21	2004-06-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7109192B2 (en) *	2002-12-03	2006-09-19	Boehringer Ingelheim Pharma Gmbh & Co Kg	Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
JP4651934B2 (ja)	2002-12-04	2011-03-16	キッセイ薬品工業株式会社	ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
US7420079B2 (en)	2002-12-09	2008-09-02	Bristol-Myers Squibb Company	Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
DE10258008B4 (de)	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de)	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2006516257A (ja) *	2003-01-03	2006-06-29	ブリストル−マイヤーズ　スクイブ　カンパニー	Ｃ−アリールグルコシドｓｇｌｔ２阻害剤の製造法
MXPA05007485A (es)	2003-01-14	2006-01-30	Arena Pharm Inc	Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
WO2004076470A2 (en)	2003-02-27	2004-09-10	Bristol-Myers Squibb Company	A non-cryogenic process for forming glycosides
ES2363941T3 (es)	2003-03-14	2011-08-19	Astellas Pharma Inc.	Derivados de c-glucósido para el tratamiento de diabetes.
US7674486B2 (en)	2003-05-14	2010-03-09	Indus Biotech Pvt. Ltd.	Synergistic composition for the treatment of diabetes mellitus
CA2528152A1 (en)	2003-06-03	2005-01-06	The Regents Of The University Of California	Compositions and methods for treatment of disease with acetylated disaccharides
JP2004359630A (ja)	2003-06-06	2004-12-24	Yamanouchi Pharmaceut Co Ltd	ジフルオロジフェニルメタン誘導体及びその塩
DE10327439A1 (de)	2003-06-18	2005-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
JO2625B1 (en)	2003-06-24	2011-11-01	ميرك شارب اند دوم كوربوريشن	Phosphoric acid salts of dipeptidyl betidase inhibitor 4
ATE411980T1 (de)	2003-07-21	2008-11-15	Smithkline Beecham Corp	(2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl) l-phenylalanylü-2-pyrrolidincarbonitril-p- toluolsulfonsäuresalz und wasserfreie kristalline formen davon
EP1679965A4 (en)	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
ES2531660T3 (es)	2003-08-01	2015-03-18	Mitsubishi Tanabe Pharma Corporation	Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
JP4131216B2 (ja)	2003-08-20	2008-08-13	Ｊｓｒ株式会社	ポリアリーレンおよびその製造方法、ならびに高分子固体電解質およびプロトン伝導膜
EP1660509B1 (de)	2003-08-26	2009-02-04	Boehringer Ingelheim International GmbH	Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7375090B2 (en) *	2003-08-26	2008-05-20	Boehringer Ingelheim International Gmbh	Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US20050085680A1 (en) *	2003-10-21	2005-04-21	Joseph Auerbach	Method for industrial decontamination
US7526806B2 (en) *	2003-11-05	2009-04-28	Cisco Technology, Inc.	Method and system for addressing intrusion attacks on a computer system
DE10355304A1 (de) *	2003-11-27	2005-06-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10359098A1 (de)	2003-12-17	2005-07-28	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
US7371732B2 (en) *	2003-12-22	2008-05-13	Boehringer Ingelheim International Gmbh	Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
DE10361133A1 (de)	2003-12-22	2005-07-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10360835A1 (de)	2003-12-23	2005-07-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
RU2766487C2 (ru)	2004-01-20	2022-03-15	Новартис Аг	Композиция и способ прямого прессования
DE102004008112A1 (de) *	2004-02-18	2005-09-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de)	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
BRPI0508259A (pt)	2004-03-04	2007-07-31	Kissei Pharmaceutical	derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
PL381247A1 (pl)	2004-03-04	2007-05-14	Kissei Pharmaceutical Co., Ltd.	Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
EP1740589A1 (de)	2004-04-10	2007-01-10	Boehringer Ingelheim International GmbH	Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel
US7741082B2 (en)	2004-04-14	2010-06-22	Bristol-Myers Squibb Company	Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
DE102004022970A1 (de)	2004-05-10	2005-12-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden
US7214702B2 (en)	2004-05-25	2007-05-08	Bristol-Myers Squibb Company	Process for producing a dipeptidyl peptidase IV inhibitor
TWI415635B (zh)	2004-05-28	2013-11-21	必治妥施貴寶公司	加衣錠片調製物及製備彼之方法
US7935723B2 (en)	2004-06-04	2011-05-03	Novartis Pharma Ag	Use of organic compounds
US7393836B2 (en) *	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
JPWO2006006496A1 (ja)	2004-07-08	2008-04-24	アステラス製薬株式会社	アズレン誘導体の製造方法及びその合成中間体
AU2005261778A1 (en)	2004-07-14	2006-01-19	Novartis Ag	Combination of DPP-IV inhibitors and compounds modulating 5-HT3 and/or 5-HT4 receptors
DE102004034690A1 (de)	2004-07-17	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en)	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (de)	2004-07-27	2006-02-02	Boehringer Ingelheim International Gmbh	D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de)	2004-08-11	2006-02-23	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004043944A1 (de)	2004-09-11	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AR051446A1 (es) *	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
DE102004048388A1 (de)	2004-10-01	2006-04-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU2005299808B2 (en)	2004-10-25	2009-08-20	Novartis Ag	Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE602005009745D1 (de)	2004-12-16	2008-10-23	Boehringer Ingelheim Pharma	Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
DE102004063099B4 (de)	2004-12-22	2009-02-12	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Thiophenglycosidderivaten
CN101103032B (zh)	2004-12-24	2011-05-11	大日本住友制药株式会社	双环吡咯衍生物
DOP2006000008A (es) *	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
GT200600008A (es) *	2005-01-18	2006-08-09		Formulacion de compresion directa y proceso
TW200637869A (en)	2005-01-28	2006-11-01	Chugai Pharmaceutical Co Ltd	The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP5264183B2 (ja) *	2005-02-23	2013-08-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
CA2600203C (en)	2005-03-22	2012-12-04	F.Hoffmann-La Roche Ag	New salt and polymorphs of a dpp-iv inhibitor
ATE453656T1 (de) *	2005-04-15	2010-01-15	Boehringer Ingelheim Int	Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en) *	2005-05-03	2010-05-25	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk)	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
GT200600218A (es)	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
MY152185A (en)	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
WO2007000445A1 (en) *	2005-06-29	2007-01-04	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AR054871A1 (es) *	2005-07-27	2007-07-25	Boehringer Ingelheim Int	Derivados de (hetero)cicloalquiletinil-bencil)-benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, sus uso y proceso para su fabricacion
UY29694A1 (es)	2005-07-28	2007-02-28	Boehringer Ingelheim Int	Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AU2006278596A1 (en)	2005-08-04	2007-02-15	Novartis Ag	Salts of vildagliptin
CA2617715A1 (en)	2005-08-11	2007-02-15	F. Hoffmann-La Roche Ag	Pharmaceutical composition comprising a dpp-iv inhibitor
WO2007025943A2 (en)	2005-08-30	2007-03-08	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AU2006289093A1 (en) *	2005-09-08	2007-03-15	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PT1931350E (pt)	2005-09-14	2014-02-12	Takeda Pharmaceutical	Administração de inibidores de dipeptidil peptidase
AR056195A1 (es) *	2005-09-15	2007-09-26	Boehringer Ingelheim Int	Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
TW200745079A (en)	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
EP1928499B1 (en)	2005-09-20	2011-06-29	Novartis AG	Use of a dpp-iv inhibitor to reduce hypoglycemic events
BRPI0616694B8 (pt)	2005-09-29	2021-05-25	Novartis Ag	processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
AU2006306420A1 (en)	2005-10-25	2007-05-03	Merck Sharp & Dohme Corp.	Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
EP1785745A1 (de)	2005-11-10	2007-05-16	Omron Electronics Manufacturing of Germany GmbH	Verfahren und Bedieneinheit zum Konfigurieren und Überwachen einer Einrichtung mit funktionaler Sicherheit
CA2633167A1 (en)	2005-12-16	2007-07-12	Merck & Co., Inc.	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
CN101341148A (zh)	2005-12-21	2009-01-07	霍夫曼-拉罗奇有限公司	新型的dpp-iv抑制剂的盐和多晶型物
CA2633484A1 (en) *	2005-12-23	2007-06-28	Novartis Ag	Condensed heterocyclic compounds useful as dpp-iv inhibitors
JP5094416B2 (ja)	2005-12-28	2012-12-12	武田薬品工業株式会社	糖尿病治療剤
JP2009522374A (ja)	2006-01-06	2009-06-11	ノバルティスアクチエンゲゼルシャフト	糖尿病処置のためのビルダグリプチンの使用
WO2007112368A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Preparation of (r)-3-aminopiperidine dihydrochloride
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
PE20080697A1 (es) *	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP2540725A1 (de)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) *	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
KR20070111099A (ko)	2006-05-16	2007-11-21	영진약품공업주식회사	시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물
EP2269583B1 (en)	2006-06-16	2014-08-13	LEK Pharmaceuticals d.d.	Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
WO2007149797A2 (en)	2006-06-19	2007-12-27	Novartis Ag	Use of organic compounds
EP2035395A2 (en)	2006-06-27	2009-03-18	Glenmark Pharmaceuticals S.A.	Novel processes for the preparation of dpp iv inhibitors
JP2010500326A (ja)	2006-08-08	2010-01-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン
WO2008020011A1 (en)	2006-08-15	2008-02-21	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
MX2009002772A (es)	2006-09-13	2009-05-28	Takeda Pharmaceutical	Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro- 2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo.
JP5235018B2 (ja)	2006-09-15	2013-07-10	エフ．ホフマン−ラロシュアーゲー	エナミンの光学分割を含むピリド［２，１−ａ］イソキノリン誘導体の製造方法
WO2008031750A2 (en)	2006-09-15	2008-03-20	F. Hoffmann-La Roche Ag	Process for the preparation of pyrido[2,1-a]isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine
WO2008034859A1 (en)	2006-09-21	2008-03-27	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008049923A1 (en)	2006-10-27	2008-05-02	Boehringer Ingelheim International Gmbh	CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
US7956201B2 (en)	2006-11-06	2011-06-07	Hoffman-La Roche Inc.	Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
WO2008062273A2 (en)	2006-11-20	2008-05-29	Cadila Pharmaceuticals Limited	Solid oral dosage form having antidiabetic drug combination
EP2114937B1 (de)	2007-01-26	2011-06-29	Sanofi-Aventis	Phenothiazin derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP2382972A1 (en)	2007-01-26	2011-11-02	Boehringer Ingelheim International GmbH	Methods for preventing and treating neurodegenerative disorders
AR065096A1 (es)	2007-02-01	2009-05-13	Takeda Pharmaceutical	Preparacion solida
TWI453041B (zh)	2007-02-01	2014-09-21	Takeda Pharmaceutical	固體型製劑
WO2008101939A1 (en)	2007-02-21	2008-08-28	Boehringer Ingelheim International Gmbh	Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
ITFI20070042A1 (it)	2007-02-21	2008-08-22	Laboratori Guidotti Spa	Formulazione farmaceutica e compressa comprendente detta formulazione.
WO2008101938A1 (en)	2007-02-21	2008-08-28	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
JP2010521492A (ja)	2007-03-15	2010-06-24	ネクティド，インク．	徐放性ビグアニド組成物、および即時性ジペプチジルペプチダーゼｉｖ阻害剤組成物を含む抗糖尿病合剤
TW200904454A (en) *	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
TW200904405A (en) *	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Pharmaceutical formulations containing an SGLT2 inhibitor
KR20120030570A (ko)	2007-04-03	2012-03-28	미쓰비시 타나베 파마 코퍼레이션	디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용
PE20090696A1 (es)	2007-04-20	2009-06-20	Bristol Myers Squibb Co	Formas cristalinas de saxagliptina y procesos para preparar las mismas
US20080287529A1 (en) *	2007-05-18	2008-11-20	Bristol-Myers Squibb Company	Crystal structures of sglt2 inhibitors and processes for preparing same
UY31291A1 (es)	2007-08-16	2009-03-31		Composicion farmacéutica que comprende un derivado de pirazol-0-glucosido
FR2920023B1 (fr)	2007-08-16	2013-02-08	Sanofi Aventis	Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
PE20090987A1 (es)	2007-08-16	2009-08-14	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CL2008002425A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
WO2009024542A2 (en)	2007-08-17	2009-02-26	Boehringer Ingelheim International Gmbh	Purin derivatives for use in the treatment of fab-related diseases
RS56990B1 (sr)	2007-09-10	2018-05-31	Janssen Pharmaceutica Nv	Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
BRPI0820535B8 (pt)	2007-11-16	2021-05-25	Novo Nordisk As	composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
CN101234105A (zh)	2008-01-09	2008-08-06	北京润德康医药技术有限公司	一种含有二甲双胍和维格列汀的药用组合物及其制备方法
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US20100330177A1 (en)	2008-02-05	2010-12-30	Merck Sharp & Dohme Corp.	Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
US8551524B2 (en)	2008-03-14	2013-10-08	Iycus, Llc	Anti-diabetic combinations
AU2009231906A1 (en)	2008-03-31	2009-10-08	Metabolex, Inc.	Oxymethylene aryl compounds and uses thereof
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es)	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en)	2008-08-15	2014-08-29	Boehringer Ingelheim Int	Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
UY32177A (es)	2008-10-16	2010-05-31	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
WO2010045656A2 (en)	2008-10-17	2010-04-22	Nectid, Inc.	Novel sglt2 inhibitor dosage forms
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es)	2009-01-29	2011-03-16	Boehringer Ingelheim Int	Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
UY32427A (es)	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
JP5685550B2 (ja)	2009-02-13	2015-03-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
US20110014284A1 (en)	2009-02-13	2011-01-20	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
AU2010212823B2 (en)	2009-02-13	2016-01-28	Boehringer Ingelheim International Gmbh	Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
DK2396005T3 (da)	2009-02-13	2026-02-09	Boehringer Ingelheim Int	Sglt2 hæmmer til at forbedre glykæmisk kontrol
JP2012528170A (ja)	2009-05-27	2012-11-12	ブリストル−マイヤーズスクイブカンパニー	別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
EP2442806A1 (en)	2009-06-15	2012-04-25	Merck Sharp & Dohme Corp.	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
EA020798B1 (ru)	2009-09-30	2015-01-30	Бёрингер Ингельхайм Интернациональ Гмбх	СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
PT2486029E (pt)	2009-09-30	2015-10-14	Boehringer Ingelheim Int	Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
NZ598170A (en)	2009-10-02	2014-06-27	Boehringer Ingelheim Int	Pharmaceutical compositions comprising bi-1356 and metformin
UY32919A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
EP2498759B1 (en)	2009-11-13	2018-08-01	AstraZeneca AB	Immediate release tablet formulations
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2547339A1 (en)	2010-03-18	2013-01-23	Boehringer Ingelheim International GmbH	Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2368552A1 (en)	2010-03-25	2011-09-28	Boehringer Ingelheim Vetmedica GmbH	1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
EP2552442A1 (en)	2010-03-30	2013-02-06	Boehringer Ingelheim International GmbH	Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
AR082091A1 (es)	2010-05-05	2012-11-14	Boehringer Ingelheim Int	Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
WO2011161161A1 (en)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Diabetes therapy
US20120283169A1 (en)	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20130035281A1 (en)	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
AR085689A1 (es) *	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US20130035298A1 (en) *	2011-07-08	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof

2008
- 2008-08-14 CL CL2008002427A patent/CL2008002427A1/es unknown
- 2008-08-14 PE PE2008001382A patent/PE20090938A1/es active IP Right Grant
- 2008-08-15 PL PL08787264T patent/PL2187879T3/pl unknown
- 2008-08-15 UY UY31296A patent/UY31296A1/es active IP Right Grant
- 2008-08-15 LT LTEP08787264.4T patent/LT2187879T/lt unknown
- 2008-08-15 HR HRP20170022TT patent/HRP20170022T1/hr unknown
- 2008-08-15 EA EA201000321A patent/EA018608B1/ru active Protection Beyond IP Right Term
- 2008-08-15 BR BRPI0815331A patent/BRPI0815331B8/pt active IP Right Grant
- 2008-08-15 WO PCT/EP2008/060736 patent/WO2009022007A1/en not_active Ceased
- 2008-08-15 RS RS20160963A patent/RS55205B1/sr unknown
- 2008-08-15 EP EP08787264.4A patent/EP2187879B1/en not_active Revoked
- 2008-08-15 CN CN201410482423.1A patent/CN104288166A/zh active Pending
- 2008-08-15 KR KR20107003411A patent/KR101491554B1/ko active Active
- 2008-08-15 TW TW103116634A patent/TW201436798A/zh unknown
- 2008-08-15 CN CN200880102911A patent/CN101784270A/zh active Pending
- 2008-08-15 SI SI200831745A patent/SI2187879T1/sl unknown
- 2008-08-15 UA UAA201002970A patent/UA100384C2/ru unknown
- 2008-08-15 ME MEP-2016-255A patent/ME02573B/me unknown
- 2008-08-15 DK DK08787264.4T patent/DK2187879T3/en active
- 2008-08-15 AR ARP080103592A patent/AR067970A1/es not_active Application Discontinuation
- 2008-08-15 ES ES08787264.4T patent/ES2602748T3/es active Active
- 2008-08-15 NZ NZ583242A patent/NZ583242A/xx unknown
- 2008-08-15 MY MYPI20100681 patent/MY152037A/en unknown
- 2008-08-15 CA CA2696558A patent/CA2696558C/en active Active
- 2008-08-15 CN CN201410482945.1A patent/CN104353077A/zh active Pending
- 2008-08-15 US US12/673,327 patent/US8551957B2/en active Active
- 2008-08-15 TW TW97131324A patent/TWI472325B/zh active
- 2008-08-15 EP EP16172707.8A patent/EP3106156A1/en not_active Withdrawn
- 2008-08-15 PT PT87872644T patent/PT2187879T/pt unknown
- 2008-08-15 JP JP2010520594A patent/JP5595914B2/ja active Active
- 2008-08-15 HU HUE08787264A patent/HUE030158T2/en unknown
- 2008-08-15 EP EP21189804.4A patent/EP3939577A1/en active Pending
- 2008-08-15 EP EP13180262.1A patent/EP2698152A1/en not_active Withdrawn
- 2008-08-15 AU AU2008288407A patent/AU2008288407B2/en active Active
- 2008-08-15 MX MX2010001696A patent/MX2010001696A/es active IP Right Grant
2009
- 2009-12-21 ZA ZA200909105A patent/ZA200909105B/xx unknown
- 2009-12-22 IL IL202886A patent/IL202886A/en active IP Right Grant
2010
- 2010-02-05 CO CO10012795A patent/CO6251239A2/es active IP Right Grant
- 2010-02-12 TN TNP2010000073A patent/TN2010000073A1/fr unknown
- 2010-02-15 MA MA32622A patent/MA31612B1/fr unknown
- 2010-02-19 EC EC2010009977A patent/ECSP109977A/es unknown
- 2010-11-11 HK HK15101597.8A patent/HK1201721A1/xx unknown
- 2010-11-11 HK HK15102815.2A patent/HK1203351A1/xx unknown
2012
- 2012-08-23 AR ARP120103117A patent/AR087657A2/es not_active Application Discontinuation
2016
- 2016-12-09 CY CY20161101277T patent/CY1118308T1/el unknown
2017
- 2017-05-05 NO NO2017020C patent/NO2017020I2/no unknown
- 2017-05-08 NL NL300872C patent/NL300872I2/nl unknown
- 2017-05-08 LT LTPA2017014C patent/LTC2187879I2/lt unknown
- 2017-05-09 CY CY2017017C patent/CY2017017I2/el unknown
- 2017-05-10 HU HUS1700020C patent/HUS1700020I1/hu unknown

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020137903A1 (en) *	1999-10-12	2002-09-26	Bruce Ellsworth	C-aryl glucoside SGLT2 inhibitors and method
US20030114390A1 (en) *	2001-03-13	2003-06-19	Washburn William N.	C-aryl glucoside SGLT2 inhibitors and method
EP1406873A2 (en) *	2001-06-27	2004-04-14	Smithkline Beecham Corporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003037327A1 (en) *	2001-10-26	2003-05-08	F. Hoffmann-La-Roche Ag	N-substituted pyrrolidin derivatives as dipeptidyl peptidase iv inhibitors
EP1500403A1 (en) *	2002-04-26	2005-01-26	Ajinomoto Co., Inc.	Preventive/remedy for diabetes
WO2004018468A2 (de) *	2002-08-21	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel
WO2004050658A1 (de) *	2002-12-03	2004-06-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel
WO2005000848A1 (en) *	2003-06-20	2005-01-06	F. Hoffmann-La Roche Ag	Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors
WO2005049022A2 (en) *	2003-11-17	2005-06-02	Novartis Ag	Use of dipeptidyl peptidase iv inhibitors
WO2005085246A1 (de) *	2004-02-18	2005-09-15	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
EP1586571A1 (en) *	2004-03-15	2005-10-19	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2005092877A1 (de) *	2004-03-16	2005-10-06	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2005116014A1 (en) *	2004-05-12	2005-12-08	Pfizer Products Inc.	Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
WO2006029769A1 (de) *	2004-09-14	2006-03-23	Boehringer Ingelheim International Gmbh	Neue 3-methyl-7-butinyl-xanthine, deren herstellung und deren verwendung als arzneimittel
WO2006040625A1 (en) *	2004-10-12	2006-04-20	Glenmark Pharmaceuticals S.A.	Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation
US20070060530A1 (en) *	2005-09-14	2007-03-15	Christopher Ronald J	Administration of dipeptidyl peptidase inhibitors
WO2007093610A1 (en) *	2006-02-15	2007-08-23	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
WO2007128761A2 (de) *	2006-05-04	2007-11-15	Boehringer Ingelheim International Gmbh	Verwendungen von dpp iv inhibitoren
US20070299076A1 (en) *	2006-06-21	2007-12-27	Pfizer Inc	Substituted 3-Amino-Pyrrolidino-4-Lactams
WO2008055870A1 (en) *	2006-11-06	2008-05-15	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008055940A2 (en) *	2006-11-09	2008-05-15	Boehringer Ingelheim International Gmbh	Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Addendum 1 to "The use of stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances" [Online] 19 June 2007 (2007-06-19), pages 1-3, XP007906327 Retrieved from the Internet:> [retrieved on 2008-11-11] page 2, paragraph 1 *

Also Published As

Publication number	Publication date
UA100384C2 (en)	2012-12-25
BRPI0815331B1 (pt)	2021-04-06
TW200914030A (en)	2009-04-01
NL300872I2 (nl)	2017-06-20
AR087657A2 (es)	2014-04-09
US20110195917A1 (en)	2011-08-11
HUS1700020I1 (hu)	2017-05-29
NO2017020I2 (no)	2018-11-26
JP2010535850A (ja)	2010-11-25
HRP20170022T1 (hr)	2017-03-10
LTPA2017014I1 (lt)	2017-05-25
EP2187879A1 (en)	2010-05-26
BRPI0815331B8 (pt)	2021-05-25
ZA200909105B (en)	2010-09-29
CO6251239A2 (es)	2011-02-21
LTC2187879I2 (lt)	2018-10-25
EP3106156A1 (en)	2016-12-21
HUE030158T2 (en)	2017-04-28
SI2187879T1 (sl)	2017-02-28
WO2009022007A1 (en)	2009-02-19
RS55205B1 (sr)	2017-01-31
CY2017017I1 (el)	2017-09-13
IL202886A (en)	2013-11-28
ME02573B (me)	2017-06-20
EP2698152A1 (en)	2014-02-19
NZ583242A (en)	2012-10-26
CN104288166A (zh)	2015-01-21
CY2017017I2 (el)	2017-09-13
MA31612B1 (fr)	2010-08-02
CA2696558C (en)	2015-11-10
ECSP109977A (es)	2010-03-31
PL2187879T3 (pl)	2017-06-30
DK2187879T3 (en)	2017-01-09
CY1118308T1 (el)	2017-06-28
PT2187879T (pt)	2017-01-06
CL2008002427A1 (es)	2009-09-11
CN101784270A (zh)	2010-07-21
ES2602748T3 (es)	2017-02-22
US8551957B2 (en)	2013-10-08
TN2010000073A1 (fr)	2011-09-26
NO2017020I1 (no)	2017-05-05
KR20100049595A (ko)	2010-05-12
PE20090938A1 (es)	2009-08-08
AU2008288407B2 (en)	2012-04-05
KR101491554B1 (ko)	2015-02-09
CN104353077A (zh)	2015-02-18
TWI472325B (zh)	2015-02-11
HK1201721A1 (en)	2015-09-11
MX2010001696A (es)	2010-03-10
AU2008288407A1 (en)	2009-02-19
MY152037A (en)	2014-08-15
EP2187879B1 (en)	2016-10-12
UY31296A1 (es)	2009-03-31
EP3939577A1 (en)	2022-01-19
BRPI0815331A2 (pt)	2020-06-09
EA201000321A1 (ru)	2010-08-30
HK1203351A1 (en)	2015-10-30
AR067970A1 (es)	2009-10-28
CA2696558A1 (en)	2009-02-19
JP5595914B2 (ja)	2014-09-24
TW201436798A (zh)	2014-10-01
LT2187879T (lt)	2016-11-25

Legal Events

Date	Code	Title	Description
2017-09-29	ND4A	Extension of term of a eurasian patent
2018-11-30	ND4A	Extension of term of a eurasian patent

Publication	Publication Date	Title
EA018608B1 (ru)	2013-09-30	Фармацевтическая композиция, содержащая глюкопиранозилзамещенное производное бензола и ингибитор dpp iv
US12115179B2 (en)	2024-10-15	Pharmaceutical composition, methods for treating and uses thereof
US10864225B2 (en)	2020-12-15	Treatment of metabolic disorders in equine animals
US20130096076A1 (en)	2013-04-18	Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor
KR20090107543A (ko)	2009-10-13	피라졸-ｏ-글리코사이드 유도체를 포함하는 약제학적 조성물
WO2009022009A1 (en)	2009-02-19	Pharmaceutical composition comprising a pyrazole-o-glucoside derivative
EA018495B1 (ru)	2013-08-30	Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
WO2009022008A1 (en)	2009-02-19	Pharmaceutical composition comprising a pyrazole-o-glucoside derivative
JP2013523681A (ja)	2013-06-17	Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
HK1143951A (en)	2011-01-21	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
HK1161544A (en)	2012-07-27	Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
HK1127612A (en)	2009-10-02	CRYSTALLINE FORM OF 1'-(1-METHYLETHYL)-4'-[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5'-METHYL-1H-PYRAZOL-3'-O-β-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS